Big Pharma Approvals — October 13, 2026

Genentech Inc received a label expansion approval for atezolizumab (TECENTRIQ) on 2026-10-08, extending an existing immuno-oncology asset; indication size and peak sales are NOT_DISCLOSED.

Genentech Inc received a label expansion for atezolizumab and hyaluronidase-tqjs (TECENTRIQ HYBREZA) on 2026-10-08, a formulation pairing that may support delivery flexibility versus intravenous dosing; competitive and commercial impact is NOT_DISCLOSED.

Amgen Inc received a label expansion for evolocumab (REPATHA) on 2026-10-09; peak sales, pricing power, and market position are NOT_DISCLOSED.

AstraZeneca AB received a label expansion for budesonide, glycopyrrolate, and formoterol fumarate (BREZTRI AEROSPHERE) on 2026-10-08; commercial metrics are NOT_DISCLOSED.

Two atezolizumab approvals within the Tecentriq franchise indicate lifecycle management, but the period data does not establish competitive share effects against other PD-(L)1 agents; competitive position is NOT_DISCLOSED.

Label expansions of established brands may face pricing pressure as payers evaluate incremental value; pricing power for REPATHA, TECENTRIQ, and BREZTRI is NOT_DISCLOSED.

Genentech can leverage two concurrent atezolizumab approvals to broaden TECENTRIQ and TECENTRIQ HYBREZA use across eligible populations.

Amgen's REPATHA expansion and AstraZeneca's BREZTRI expansion extend mature franchises into additional patient populations.

Genentech received two atezolizumab-related approvals in one period, including a subcutaneous hyaluronidase-based formulation, suggesting active franchise lifecycle investment.

Amgen and AstraZeneca both received label expansions for established cardiovascular and respiratory brands, indicating broad-based growth in mature portfolios.

{"entity" => "TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs)", "reason" => "Subcutaneous formulation approved as a label expansion on 2026-10-08; uptake versus intravenous TECENTRIQ is a key commercial question.", "trigger" => "Initial launch metrics and payer coverage decisions for the subcutaneous formulation"}

{"entity" => "REPATHA (evolocumab)", "reason" => "Label expansion approved 2026-10-09 for Amgen; incremental patient population and pricing are NOT_DISCLOSED.", "trigger" => "Guideline inclusion and payer formulary updates for the expanded indication"}

{"entity" => "BREZTRI AEROSPHERE", "reason" => "Label expansion approved 2026-10-08 for AstraZeneca in a competitive inhaled respiratory class.", "trigger" => "Competitive response from other triple-therapy inhaler sponsors and payer tiering decisions"}